Clinical Trials
34 trialsTAPUR
American Society of Clinical Oncology
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Loyola University
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
TOR-AML
Goethe University
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
VESTOR
Institut Bergonié
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
POEM
MedSIR
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
University of Wisconsin, Madison
MetAction
Oslo University Hospital
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
AML1107
Gruppo Italiano Malattie EMatologiche dell'Adulto
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
STORM
University Hospital Heidelberg
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
AGO Study Group
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
CCI-779 in Treating Patients With Metastatic Melanoma
City of Hope Medical Center
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Oncology Specialists, S.C.
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
TEMHEAD
Hannover Medical School
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
TORAVA
Centre Leon Berard
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
Jonsson Comprehensive Cancer Center
Temsirolimus as Second-line Therapy in HCC
University of Tennessee Cancer Institute
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
Central European Society for Anticancer Drug Research
Temsirolimus-RCC-imaging
Radboud University Medical Center
Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
Hellenic Cooperative Oncology Group
TIRASMUS
Vejle Hospital
A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme
Rigshospitalet, Denmark